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GOYA was a randomized phase 3 study comparing obinutuzumab plus cyclophosphamide,
doxorubicin, vincristine, andprednisone (CHOP) vs standard-of-care rituximab plus CHOP in
patients with previously untreated diffuse large B-cell lymphoma (DLBCL). This
retrospective analysis of GOYA aimed to assess the association between progression-free
survival (PFS) and overall survival (OS) with positron emission tomography (PET)–based
complete response (CR) status. Overall, 1418 patients were randomly assigned to receive
8 21-day cycles of obinutuzumab (n5 706) or rituximab (n5 712) plus 6 or 8 cycles of CHOP.
Patients received a mandatory fluoro-2-deoxy-D-glucose–PET/computed tomography scan at
baseline and end of treatment. After a median follow-up of 29 months, the numbers of
independent review committee–assessed PFS and OS events in the entire cohort were 416
(29.3%) and 252 (17.8%), respectively. End-of-treatment PET CR was highly prognostic for
PFS and OS according to Lugano 2014 criteria (PFS: hazard ratio [HR], 0.26; 95% confidence
interval [CI], 0.19-0.38; P , .0001; OS: HR, 0.12; 95% CI, 0.08-0.17; P , .0001), irrespective of
international prognostic index score and cell of origin. In conclusion, the results from this
prospectively acquired large cohort corroborated previously published data from
smaller sample sizes showing that end-of-treatment PET CR is an independent predictor
of PFS and OS and a promising prognostic marker in DLBCL. Long-term survival analysis
confirmed the robustness of these data over time. Additional meta-analyses including
other prospective studies are necessary to support the substitution of PET CR for PFS as
an effective and practical surrogate end point. This trial was registered at www.
clinicaltrials.gov as #NCT01287741.
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Introduction
Although diffuse large B-cell lymphoma (DLBCL) is potentially
curable with standard-of-care treatment combining the anti-
CD20 antibody rituximab with cyclophosphamide, doxorubicin,
vincristine, and prednisone (CHOP), patients experiencing
disease relapse after first-line therapy have poor outcomes.1
Therefore, development of new treatments to improve clinical
outcomes is an essential aspect of improving patient outcomes.
However, inherent to lymphoma registry trials, the commonly used
clinical end points require extended study duration to determine
efficacy of novel drugs. In clinical studies, median progression-free
survival (PFS) or event-free survival is generally not reached by the
time of primary analysis; follow-up of at least 2 years is required to
determine treatment efficacy. This protracted observation period
may be superseded with a faster prognostic surrogate end point for
PFS that could be used for accelerated approval of new treatment
options, which would provide fast access to efficacious antilym-
phoma drugs and early termination of the development phase of
potentially ineffective drugs.
Positron emission tomography (PET) imaging with fluoro-2-deoxy-
D-glucose (FDG), particularly when integrated with PET/computed
tomography (CT), has proven a valuable tool for assessment of
treatment response, because it can distinguish active lymphoma
from residual fibrotic masses.2 Consequently, FDG PET/CT has
played a key role in staging and assessment of response to
treatment since the development of revised response criteria for
malignant lymphoma (Cheson 2007 criteria),3 further supported
by updated response guidelines4 incorporating the Deauville
5-point scale as a treatment assessment tool (standard Lugano
2014 criteria).
In small DLBCL cohorts, end-of-treatment PET was found to correlate
with patient outcomes, as measured by PFS, event-free survival, and
overall survival (OS).5-9 However, there is a paucity of published data
from large-scale phase 2 or 3 clinical trials that could help guide
oncology practice on use of end-of-induction PET/CT as a substitute
for PFS and potential surrogate marker for outcomes.
GOYA was a phase 3 study comparing obinutuzumab, a glycoengi-
neered type 2 anti-CD20 antibody, plus CHOP (G-CHOP) vs rituximab
plus CHOP (R-CHOP) in patients with previously untreated DLBCL.
The study did not meet the primary end point, and no difference in PFS
was found between G-CHOP and R-CHOP after a median
observation of 29 months (28.5% vs 30.2%; hazard ratio [HR],
0.92; 95% confidence interval [CI], 0.76-1.11; P 5 .39).10 In this
prespecified secondary analysis, the objective was to investigate
correlation of end-of-treatment FDG PET responses with PFS to
provide further evidence for PET complete response (CR) assessed
according to Cheson 2007 criteria and PET CR assessed according
to standard Lugano 2014 criteria as alternative end points to PFS in
DLBCL.
Methods
Study design and participants
GOYA was an open-label, multicenter, randomized phase 3 study.
The GOYA study design and patient population have been previously
described.11 In brief, eligible patients were age $18 years with
previously untreated, histologically documented, CD201 DLBCL.
Patients were randomly assigned 1:1 to receive 8 21-day cycles
of obinutuzumab at 1000 mg on days 1, 8, and 15 of cycle 1
and day 1 of cycles 2 to 8 or rituximab at 375mg/m2 on day 1 of cycles
1 to 8, plus 6 or 8 cycles of standard-dose CHOP chemotherapy
(supplemental Figure 1).
GOYA was conducted in accordance with the International Confer-
ence on Harmonisation guidelines for Good Clinical Practice. The
protocol was approved by the ethics committees of participating
centers. All patients provided written informed consent.
Clinical assessments
FDG PET/CT scanning was mandatory at sites where a PET/CT
scanner was available. Patients had an FDG PET/CT scan at
baseline (1-35 days before first dose of study treatment) and end of
treatment (6-8 weeks after last dose of antibody) or in the event of
early discontinuation (4-8 weeks after last dose of antibody). All
PET/CT scans followed a standardized protocol with prespecified
time windows (data supplement). Blood glucose values were
required to be,200 mg/dL in all patients, and all scans were to be
obtained within the specified time window. Bone marrow biopsy
was also performed at baseline.
Treatment response (CT plus PET scan) at end of treatment was
prospectively assessed by independent review committee accord-
ing to Cheson 2007 criteria, which uses mediastinal blood pool as
the cutoff to define a positive result3 (defined as PET CR or at least
partial response [PR]; supplemental Table 1). Response was also
assessed retrospectively according to Lugano 2014 criteria, which
uses liver background uptake as the cutoff to define a positive
result4,11 (defined by PET as CR or at least PR; supplemental
Table 1). Deauville scores of 1 to 3 were considered to indicate
complete metabolic response and 4 to 5 to indicate noncomplete
metabolic response. In addition, a modification to Lugano 2014
criteria was applied (PR confirmed by CT; in patients with bone
marrow involvement at baseline, CR had to be confirmed with
negative bone marrow at end of treatment).
The independent review committee comprised 2 expert radiol-
ogists who were blinded to clinical outcome and a third radiologist
to adjudicate on differences in attributed responses. The final
independent review committee response was assessed by an
independent clinician who combined radiological data with
bone marrow and other biopsy information. The independent
review committee was used only for the primary analysis, and
subsequent tumor response and progression continued to be
assessed by the investigator using conventional clinical, laboratory,
and CT examinations.
Cell-of-origin analysis
Cell-of-origin classification (germinal center B cell–like [GCB], activated
B cell–like [ABC], or unclassified) was determined using the Nano-
String Lymphoma Subtyping Research-Use-Only assay (NanoString
Technologies, Inc., Seattle, WA).12,13
Outcomes
The primary objective was to determine the prognostic value of end-
of-treatment PET-based response using Lugano 2014 criteria with
respect to independent review committee–assessed PFS and OS
in patients with previously untreated DLBCL.
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Secondary objectives were to investigate any difference in PFS
prediction between Cheson 2007 or standard Lugano 2014
criteria and modified Lugano 2014 criteria and evaluate the long-
term prognostic value of end-of-treatment PET-based response
using standard Lugano 2014 criteria with respect to investigator-
assessed PFS and OS.
Exploratory analyses included correlation of PET-based response
by standard and modified Lugano 2014 criteria, with stratification of
patients according to international prognostic index (IPI) scores and
cell of origin, where data were available.
Statistical analysis
Analyses were conducted in the PET intent-to-treat (ITT) popula-
tion, which consisted of all randomly assigned patients who had
a baseline PET scan with detectable lesions. Treatment arms were
pooled for this secondary imaging analysis.
Landmark independent review committee–assessed PFS and OS
from end of treatment (henceforth PFS and OS) were estimated
using the Kaplan-Meier method and compared according to PET
CR status by log-rank test. For each landmark analysis, patients
were included if they were at risk (according to the end point
considered) 1 day after their end-of-treatment visit, with a particular
emphasis on the 2.5 years after end-of-treatment visit (;3 years
after random assignment). Positive predictive values (PPVs) and
negative predictive values (NPVs) were read from Kaplan-Meier
estimates of the landmark PFS rate 2.5 years after end of treatment,
where PPV was 1 minus the landmark PFS rate among patients
without PET CR and NPV was the landmark PFS rate among
patients with PET CR.14 Covariate effects were estimated using
multivariable Cox models. Association between PFS and PET status
at end of treatment, as well as study stratification factors (IPI score,
number of planned CHOP cycles [6 or 8], and geographic region),
was assessed using a multivariable Cox model. A P value,.05 was
considered significant, and statistical analyses were conducted
using SAS software (version 9.4; SAS Institute, Inc., Cary, NC).
Results
Patient population and baseline demographics
Patient disposition for the GOYA study has been previously
described.10 Of the 1418 patients randomly assigned in the
GOYA study between July 2011 and June 2014, 1346 (95%)
had evaluable baseline and end-of-treatment PET/CT scans. Of
these, 1334 (99%) had a PET/CT scan with detectable lesions
at baseline (PET ITT; supplemental Figure 1). Baseline demograph-
ics and disease characteristics were similar between PET ITT and
overall GOYA ITT populations (supplemental Table 2).
Concordance between response criteria for
malignant lymphoma
Independent review committee–assessed FDG PET/CT response
rates at end of treatment according to Cheson 2007 and Lugano
2014 criteria demonstrated high concordance, with 79% (917 of
1160 patients with valid response) agreement in the classification
of response (supplemental Table 2). Concordance between the
classification of patients as PET CR according to standard and
modified Lugano 2014 criteria was excellent (95%; supplemental
Table 3).
Prognostic value of end-of-treatment FDG PET/CT
response for PFS and OS
At the time of final analysis, with additional follow-up (median,
47.7 months), the numbers of investigator-assessed PFS and
OS events in the entire cohort were 457 (32.2%) and 290
(20.5%), respectively. End-of-treatment PET CR was confirmed
to be highly prognostic of PFS and OS when using standard
Lugano 2014 response criteria (Figure 1), with a 2.5-year landmark
PFS rate of 83.5% vs 51.2% for patients with no PET CR and a 2.5-
year OS rate of 92.9% vs 56.8% for patients with no PET CR. As
such, at the 2.5-year landmark, the PPV for PFS was 48.8% in
patients without PET CR, and the NPV in patients with PET CR was
83.5%; the PPV for OS was 43.2% in patients without PET CR, and
the NPV was 92.9% for patients with PET CR.
At the time of primary analysis, after a median follow-up of 29
months, the numbers of independent review committee–assessed
PFS and OS events in the entire cohort were 416 (29.3%) and
252 (17.8%), respectively. End-of-treatment PET CR was highly
prognostic for PFS and OS using Cheson 2007 and standard and
modified Lugano 2014 criteria (supplemental Figures 2 and 3). Of
the 1096 patients still at risk at end of treatment, only 122 (12.7%)
of 963 with end-of-treatment PET CR and 43 (32.3%) of 133
without end-of-treatment PET CR had relapsed disease by the time
of this analysis (standard Lugano 2014 criteria; supplemental
Figure 2C). Landmark PFS rates (2.5 years after end of treatment
[ie, 3 years after random assignment]) were higher in patients with
end-of-treatment PET achieving PET CR vs those with no PET CR,
according to Cheson 2007 (2.5-year landmark PFS, 85.6% vs
64.7%; HR, 0.35; 95% CI, 0.26-0.47; P , .0001) and standard
Lugano 2014 criteria (2.5-year landmark PFS, 85.7% vs 53.5%;
HR, 0.26; 95% CI, 0.19-0.38; P , .0001; supplemental Figure 2).
Furthermore, landmark OS rates 2.5 years after end of treatment
were improved in patients with end-of-treatment PET achieving PET
CR vs those with no PET CR, according to Cheson 2007 (93.4% vs
67.0%; HR, 0.18; 95% CI, 0.13-0.25; P , .0001) and standard
Lugano 2014 criteria (93.5% vs 55.6%; HR, 0.12; 95% CI, 0.08-
0.17; P , .0001; supplemental Figure 3).
In exploratory subgroup analysis, 2.5-year investigator-assessed
landmark PFS rates were higher in patients with PET CR vs those
without, irrespective of IPI score, according to standard Lugano
2014 criteria (Figure 2). Among patients with PET CR, those with
IPI scores of 0 to 2 had lower PFS than those with scores of 3 to 5
(2.5-year PFS rate, 77.4% vs 87.9%; Figure 2). PFS was higher in
patients with PET CR vs those without, irrespective of cell of origin.
Among patients with PET CR, landmark investigator-assessed PFS
was significantly lower for the ABC/unclassified group vs the GCB
group (HR, 1.56; 95% CI, 1.15-2.12; P5 .0445; Figure 3). Similarly,
in patients without PET CR, PFS was lower in the ABC/unclassified
group vs the GCB group (Figure 3).
Multivariate analyses confirmed that end-of-treatment PET CR vs no
PET CR was highly prognostic for PFS and OS, independent of IPI,
number of planned CHOP cycles, and geographic region (Table 1;
supplemental Table 4).
Discussion
This secondary analysis of the phase 3 GOYA trial demonstrates
that end-of- treatment FDG PET, as assessed by standard4,11
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Lugano 2014 response criteria, is prognostic for PFS in patients with
previously untreated DLBCL. Notably, at the time of primary analysis,
of the patients with PET CR at end of treatment determined by
standard Lugano criteria, only 12.7% had disease progression,
compared with 32.3% of those without PET CR. Furthermore,
the PET CR group had significantly longer OS after end of
treatment in comparison with the group with no PET CR. These
results from a phase 3 trial, 1 of the largest to date determining
the prognostic value of FDG PET, are consistent with previously
reported smaller studies indicating the potential for using end-
of-treatment PET CR as an independent prognostic factor for
relapse or progressive disease in patients with DLBCL un-
dergoing first-line therapy.5,7,9,15-18
In a prospective study of 138 patients with DLBCL that used the
Deauville 5-point scale for assessment, Mamot et al4 demon-
strated that end-of-treatment PET positivity by central review was
associated with a significantly higher 2-year event-free survival
rate in patients with vs without PET CR after R-CHOP treatment
(71.5% vs 24.0%; P , .001).9 In a population-based cohort of
223 patients with DLBCL treated with R-CHOP or R-CHOP–like
immunochemotherapy, Bishton et al15 showed higher 5-year
OS rates in patients with vs without PET CR using Cheson
2007 criteria (75.4% vs 35.6%; P 5 .0001). In that study,
however, patients classified as high risk (.6) according to the
National Comprehensive Cancer Network (NCCN) IPI score,
which risk stratifies patients based on 5 clinical variables (age,
Eastern Cooperative Oncology Group performance status, lactate
dehydrogenase, extranodal sites, and Ann Arbor stage) providing
scores ranging from 0 to 8,19 had poor outcomes (5-year PFS and
OS rates both 38.5% in patients with PET CR), whereas patients
with NCCN IPI scores of 0 to 5 had excellent outcomes (5-year
PFS and OS rates of 75.9% to 94.1%).15
More recently, in a retrospective study of 185 patients with de
novo DLBCL where the Deauville 5-point scale was used to
assess treatment outcomes, Kanemasa et al16 reported that
only 13.2% of patients with end-of-treatment PET CR experienced
disease relapse after treatment with R-CHOP or R-CHOP–like
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Figure 1. Investigator-assessed survival from end of treatment according to PET CR status assessed by standard Lugano 2014 response criteria (PET ITT
population). (A) PFS (n 5 1092). (B) OS (n 5 1145). Final data cutoff, 31 January 2018. According to standard Lugano 2014 response criteria, no PET CR includes PR,
nonresponse, and progressive disease patients with no progressive disease event by primary end point definition (investigator-assessed PFS). P values by log-rank test.
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had significantly longer OS and PFS than those with CT CR (5-year
OS rate, 87.5% vs 62.4%; P 5 .003; 5-year PFS rate, 81.4% vs
60.2%; P 5 .009).
Consistent with the findings of Bishton et al,15,20 Kanemasa
et al,16 using data collected for the NCCN non-Hodgkin lymphoma
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IPI 0-2 PET CR
IPI 0-2 no PET CR
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Figure 2. Kaplan-Meier analysis of investigator-assessed PFS according to PET CR status for patients with IPI scores of 0 to 2 and 3 to 5 by standard
Lugano 2014 criteria (PET ITT population, n 5 1092). According to standard Lugano 2014 response criteria, no PET CR includes PR, nonresponse, and progressive
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Figure 3. Kaplan-Meier analysis of investigator-assessed PFS according to cell of origin for patients with and without PET CR by standard Lugano 2014
criteria (PET ITT population, n 5 1092). According to standard Lugano 2014 response criteria, no PET CR includes PR, nonresponse, and progressive disease patients
with no progressive disease event by the primary end point definition (investigator-assessed PFS). P values by log-rank test.
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stratified according to NCCN IPI score, those with high-risk scores
(.6) had a particularly poor prognosis, despite achieving PET CR,
with 5-year PFS and OS rates of 53.8% and 61.8%, respectively. In
contrast, the multivariate analysis in our study showed that PET CR
was highly prognostic for PFS and OS using standard Lugano
2014 criteria, independent of IPI, number of planned CHOP cycles,
and geographic region.
A number of characteristics of the aforementioned retrospective
studies could have contributed to the differences in subgroup
results compared with the present analysis. These include study
design, potential selection bias, limited patient numbers in each
stratification group, use of suboptimal and varying response in-
terpretation criteria, and old-generation PET scanners. It is also
important to note that IPI continues to be used as a risk scoring
system in PET-staged DLBCL patients.21 Although treatment
protocols for the abovementioned studies differed from ours, the
clear congruence was that risk of disease relapse or progression
was significantly reduced for patients with end-of-treatment PET
CR compared with those without.
Assignment of DLBCL into cell-of-origin subtypes may be important
for better directing targeted therapies with selective biological
activity for either the GCB or ABC subgroup. Consistent with
previous reports by Scott et al22 and Painter et al23, the primary
analysis of the GOYA study suggested that GCB subtype was
associated with better outcomes in comparison with ABC and
unclassified subtypes, irrespective of treatment arm.10 In this
subsequent analysis, we demonstrated that the 2.5-year PFS
rate was higher in patients with PET CR vs those without,
irrespective of cell of origin. Kanemasa et al16 found that among
patients with PET CR, the GCB subgroup had a better 5-year
PFS rate than those with non-GCB DLBCL (94.8% vs 64.2%;
P5 .017). However, that study was performed in a retrospective
cohort of only 146 patients. In our study, the PET CR/no PET CR
survival curves diverged to a greater extent for the ABC/unclassified
subgroup than for the GCB subgroup, which may provide further
credence to the heterogeneity of DLBCL. Additional genetic
complexity within each subtype was recently discovered, which
has expanded the landscape of recurrent genetic drivers.24,25
Lugano 2014 criteria became available after the initiation and during
the conduct of this study. Interestingly, in our study, modification of
Lugano 2014 criteria by integrating bone marrow biopsy results into
the final PET CR definition did not significantly improve the
prognostic value of end-of-treatment PET imaging, suggesting that
standard Lugano 2014 criteria may be sufficient in future studies.
Only 5% of patients showed no PET CR according to modified
Lugano 2014 criteria in cases where standard Lugano 2014 criteria
indicated PET CR. Similarly, Kanemasa et al16 observed bone
marrow relapse in only 2.6% of patients who achieved PET CR.
Given the conventional use of Lugano 2014 criteria in response
assessment, it has been proposed that investigations should
continue to evaluate the potential value of bone marrow biopsy in
DLBCL when applying these criteria.26
Lugano 2014 criteria are superior to International Harmonisation
Project criteria, yielding fewer false-positive results and improving
categorization of response classification. Our data showed high
concordance with 79% agreement in the classification of response
with overlapping 2.5-year landmark PFS at 86% using these
2 criteria sets. There was a trend toward better HR for PET CR
when determined by Lugano 2014 criteria vs Cheson 2007 criteria,
reflecting improvement in false-positive rates.
The clinical impact of using PET CR as a surrogate efficacy end
point could be significant. Removing the need for long follow-up
periods required to establish PFS may allow early efficacy interim
analyses to expedite and shorten the duration of phase 3 trials and
clinical development of new treatments. Notably, the predictive
value of negative end-of-treatment PET is higher than that of
a positive result, and this finding is in line with previous reports. This
may in turn lead to underrating of an otherwise effective treatment in
some patients. A positive PET result may not be highly predictive of
an unfavorable outcome, and this should be weighed against the
potential benefit of early efficacy analysis. It must be acknowledged
that the results of this study warrant further confirmation by other
large data from phase 3 trials before adopting PET CR as
a surrogate end point alternative to PFS. Considering the
phenotypical and genotypical heterogeneity of DLBCL, it is
conceivable that parameters additional to PET CR could be
harnessed to increase accuracy of prediction. Analysis of data
from the GOYA trial using PET-derived measures found that
baseline total metabolic tumor volume and tumor lesion glycolysis
measurements were predictors of PFS and OS in DLBCL after first-
line immunochemotherapy.27 Ultimately, evidence from additional
front-line trials, together with meta-analysis of large, prospective,
controlled data sets, is needed to gain the required knowledge to
begin reducing our reliance on assessment of PFS or OS.
Several other limitations of the current analysis should be acknowl-
edged. Although GOYA was a prospective study, response assess-
ment by Lugano 2014 was performed retrospectively. However, this
limitation is mitigated by the systematic acquisition of PET data across
almost all centers, inclusion of central imaging review, use of strict
quality controls for data acquisition and analysis, and large sample size.
Although the 2 study arms were combined for this analysis, this is
unlikely to have had a negative impact, because there was no significant
treatment effect in the GOYA study. Ideally, a larger group of patients
with cell-of-origin data available would have strengthened the findings,
with RNA extraction and cell-of- origin classification only possible in 933
patients.
In summary, this study demonstrated that end-of-treatment PET
CR is highly prognostic for PFS and OS in DLBCL after first-line
immunochemotherapy, using Cheson 2007 and standard Lugano
2014 response criteria. Furthermore, the prognostic value of end-
of-treatment PET CR in relation to PFS and OS is sustained over
time. Importantly, this is the largest prospectively acquired patient
Table 1. Cox multivariate regression model for independent review




PET CR vs no PET CR* 0.28 (0.21-0.38) 0.17 (0.12-0.23)
P , .0001† P , .0001†
*Standard Lugano 2014. Model included PET status at end of treatment and stratification
factors: IPI risk group (low-intermediate, high-intermediate, or high), n of planned CHOP
cycles (6 or 8), and geographic region (Asia, eastern European Union, western European
Union, North America, or other).
†Log-rank test.
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population to date in which the prognostic value of FDG PET has
been confirmed in patients with DLBCL. In addition, cell of origin
remained associated with prognosis in patients with PET CR,
whereas IPI did not. These results support the potential for using
end-of-treatment PET CR as a surrogate marker of overall outcome
in DLBCL patients with GCB and ABC/unclassified subtypes.
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